As we enter the new year, CIRM’s 2017 Annual Report will be posted in less than two weeks! Here’s one of the people we are profiling in the report, a patient who took part in a CIRM-funded clinical trial. In March of 2015, Tom Howing was diagnosed with stage 4 cancer. Over the next 18 … Continue reading How Tom Howing turned to stem cells to battle back against a deadly cancer
CIRM
Budgeting for the future of the stem cell agency
Budgets are very rarely exciting things; but they are important. For example, it’s useful for a family to know when they go shopping exactly how much money they have so they know how much they can afford to spend. Stem cell agencies face the same constraints; you can’t spend more than you have. Last week … Continue reading Budgeting for the future of the stem cell agency
A funny thing happened on my way to a PhD: one scientists change of mind and change of direction
Laurel Barchas is an old and dear friend of the communications team here at CIRM. As a student at U.C. Berkeley she helped us draft our education portal – putting together a comprehensive curriculum to help high schools teach students about stem cells in a way that met all state and federal standards. But a … Continue reading A funny thing happened on my way to a PhD: one scientists change of mind and change of direction
FDA creates a forum for patients to guide its decision making
It’s not hard to find people who don’t like the US Food and Drug Administration (FDA), the government agency that, among other things, regulates medical therapies. In fact, if you type “do people like the FDA?” into an internet search engine you’ll quickly find out that for a lot of people the answer is “no”. … Continue reading FDA creates a forum for patients to guide its decision making
Family, faith and funding from CIRM inspire one patient to plan for his future
Having been to many conferences and meetings over the years I have found there is a really simple way to gauge if someone is a good speaker, if they have the attention of people in the room. You just look around and see how many people are on their phones or laptops, checking their email … Continue reading Family, faith and funding from CIRM inspire one patient to plan for his future
Stem cell agency funds Phase 3 clinical trial for Lou Gehrig’s disease
At CIRM we don’t have a disease hierarchy list that we use to guide where our funding goes. We don’t rank a disease by how many people suffer from it, if it affects children or adults, or how painful it is. But if we did have that kind of hierarchy you can be sure that … Continue reading Stem cell agency funds Phase 3 clinical trial for Lou Gehrig’s disease
CIRM & NIH: a dynamic duo to advance stem cell therapies
There’s nothing more flattering than to get an invitation, out of the blue, from someone you respect, and be told that they are interested in learning about the way you work, to see if it can help them improve the way they work. That’s what happened to CIRM recently. I will let Randy Mills, who … Continue reading CIRM & NIH: a dynamic duo to advance stem cell therapies
Baseball’s loss is CIRM’s gain as Stanford’s Linda Boxer is appointed to Stem Cell Agency Board
One of the things that fascinates me is finding out how people end up in the job they have, the job they love. It is rare that the direction they started out on is the one they end on. Usually, people take several different paths, some intended, some unintended, to get to where they want … Continue reading Baseball’s loss is CIRM’s gain as Stanford’s Linda Boxer is appointed to Stem Cell Agency Board
jCyte gets FDA go-ahead for Fast Track review process of Retinitis Pigmentosa stem cell therapy
When the US Congress approved, and President Obama signed into law, the 21st Century Cures Act last year there was guarded optimism that this would help create a more efficient and streamlined, but no less safe, approval process for the most promising stem cell therapies. Even so many people took a wait and see approach, … Continue reading jCyte gets FDA go-ahead for Fast Track review process of Retinitis Pigmentosa stem cell therapy
CIRM’s Randy Mills leaving stem cell agency to take on new challenge
Some news releases are fun to write. Some less so. The one that CIRM posted today definitely falls into that latter group. It announced that CIRM’s President and CEO, Randy Mills, is leaving us to take up the role of President and CEO at the National Marrow Donor Program – NMPD/Be The Match. It’s a … Continue reading CIRM’s Randy Mills leaving stem cell agency to take on new challenge
The Stem Cellar 